The Transport Minister has laid out a vision for boosting Auckland's urban density in a speech to a business group.
The Government will invest funding to remove the level crossings in Takanini and Glen Innes and replace them with ...
J.P. Morgan analyst Casey Woodring maintained a Hold rating on Charles River Labs (CRL – Research Report) yesterday and set a price target of ...
As promised, the restructuring initiatives taking place at Charles River Labs (NYSE: CRL) have resulted in a reduced ...
The Government will shell out up to $200 million to remove level crossings “universally loathed” by motorists to help speed up Aucklanders’ journey times when the City Rail Link (CRL) opens. The ...
Q4 2024 Earnings Call Transcript February 19, 2025 Charles River Laboratories International, Inc. beats earnings expectations ...
Barclays lowered the firm’s price target on Charles River (CRL) to $160 from $166 and keeps an Equal Weight rating on the shares post the Q4 ...
Despite a challenging year, Charles River Laboratories International Inc (CRL) focuses on restructuring and strategic growth ...
Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize.
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Charles River Laboratories, the largest corporate recipient of NIH funding in Mass., is not overly concerned with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results